Damien Zanker
Head of Clinical Manufacturing Cartherics Pty Ltd
Seminars
Thursday 10th September 2026
Manufacturing iPSC Therapies at Scale, Advancing Off-the-Shelf CAR-NK Production
11:30 am
- Establishing clonal iPSC master cell banks and controlled differentiation workflows to ensure product consistency, scalability, and supply security
- Embedding genetic engineering at the iPSC stage to support robust downstream manufacturing, including enhanced persistence and functional stability of CARNK cells
- Advancing CTH 401, an iPSC-derived TAG 72 CAR NK therapy, through manufacturing-led IND enabling activities ahead of first-in-human studies in ovarian cancer
